Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...

Current health news highlights include debates over Medicare pricing for drugs like Ozempic and Wegovy, management shifts ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...